Notificação de entrada na fase nacional - PCT
#1.3
10/04/2022
RPI 2700
Application data
Number
112022015825Type
Filing
Publication
PCT
EP2021053384 The application was filed at the INPI on 02/11/2021. It awaits formal examination and publication in the RPI gazette.
Latest action published by the INPI: 10/04/2022. We update with every new RPI gazette, published weekly.
Applicants
JANSSEN PHARMACEUTICA N.V.
BE
Inventors
M. M. (pessoa física)
US
IPC Classification
Priority claims
US
62/975,526 · 02/12/2020
US
63/025,817 · 05/15/2020
US
63/055,187 · 07/22/2020
US
63/078,205 · 09/14/2020
US
63/078,736 · 09/15/2020
US
63/083,316 · 09/25/2020
Abstract
INIBIDORES DE TIROSINA QUINASE FGFR E AGENTES ANTI-PD1 PARA O TRATAMENTO DE CARCINOMA UROTELIAL. São revelados aqui métodos de tratamento de carcinoma urotelial. Em particular, os métodos revelados incluem terapias de combinação para o tratamento de carcinoma urotelial que compreende administrar um inibidor de receptor do fator de crescimento de fibroblasto (FGFR) e um anticorpo anti-PD1 ou fragmento de ligação ao antígeno do mesmo.
Publications in the Brazilian Industrial Property Gazette (RPI).
#1.3
10/04/2022
RPI 2700
#1.1
08/23/2022
RPI 2694
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.